|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013089,
umls-concept:C0030705,
umls-concept:C0031437,
umls-concept:C0205170,
umls-concept:C0205210,
umls-concept:C0278488,
umls-concept:C0871261,
umls-concept:C1274040,
umls-concept:C1521750,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:dateCreated |
2010-11-4
|
|
pubmed:abstractText |
We analyzed the responses to first line treatment and clinical outcomes of metastatic breast cancer patients treated with palliative doxorubicin/cyclophosphamide (AC) according to molecular cancer subtype.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1471-2407
|
|
pubmed:author |
pubmed-author:AhnJin SeokJS,
pubmed-author:ChangMyung HeeMH,
pubmed-author:ChoEun YoonEY,
pubmed-author:ChoiYoon LaYL,
pubmed-author:ImYoung-HyuckYH,
pubmed-author:JiSang HoonSH,
pubmed-author:JunHyun JungHJ,
pubmed-author:KimKyoung HaKH,
pubmed-author:LimDo Hyoungdo H,
pubmed-author:ParkMin JaeMJ,
pubmed-author:ParkYeon HeeYH,
pubmed-author:UhmJi EunJE,
pubmed-author:YiSeong YoonSY
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
527
|
|
pubmed:meshHeading |
pubmed-meshheading:20920367-Adult,
pubmed-meshheading:20920367-Aged,
pubmed-meshheading:20920367-Antineoplastic Agents,
pubmed-meshheading:20920367-Breast Neoplasms,
pubmed-meshheading:20920367-Cohort Studies,
pubmed-meshheading:20920367-Cyclophosphamide,
pubmed-meshheading:20920367-Doxorubicin,
pubmed-meshheading:20920367-Female,
pubmed-meshheading:20920367-Humans,
pubmed-meshheading:20920367-Immunohistochemistry,
pubmed-meshheading:20920367-Middle Aged,
pubmed-meshheading:20920367-Neoplasm Metastasis,
pubmed-meshheading:20920367-Receptor, erbB-2,
pubmed-meshheading:20920367-Receptors, Estrogen,
pubmed-meshheading:20920367-Receptors, Progesterone,
pubmed-meshheading:20920367-Retrospective Studies,
pubmed-meshheading:20920367-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype.
|
|
pubmed:affiliation |
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
